Form 4: Capricor Therapeutics Director Exercises Stock Options and Disposes of Shares

Frank Litvack, a director at Capricor Therapeutics, exercised stock options to acquire 25,000 shares and disposed of 2,543 shares to cover the exercise price.

Summary

• On March 3, 2025, Frank Litvack, a director of Capricor Therapeutics, exercised stock options to acquire 25,000 shares of common stock at a price of $1.39 per share.
• Simultaneously, Litvack disposed of 2,543 shares at $13.67 per share to cover the exercise price through a 'net exercise' of the options.
• Following these transactions, Litvack directly owns 129,839 shares and indirectly owns 46,278 shares held in a family trust.
• The stock options were granted on March 3, 2015, and adjusted for a reverse stock split and share reprice.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their holdings in the company.

Comparison to Industry Standards

• Insider transactions are a normal part of corporate governance and are regularly disclosed by executives and directors in publicly traded companies.
• The details provided in the Form 4 filing are consistent with standard reporting requirements set by the SEC.
• Comparable companies such as Amgen, Gilead, and Biogen also have similar insider transaction filings when their executives exercise options or trade shares.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.
• The exercise of options and subsequent sale of shares could have a minor impact on the stock price.

Key Dates